Annick Desjardins
Associate Professor of Neurosurgery
Campus mail:
Duke Box 3624, Durham, NC 27710
Phone:
(919) 684-5301
Email address:
annick.desjardins@duke.edu
Education and Training
- Fellow in Neuro-Oncology, Medicine, Duke University, 2003 - 2005
- Resident, Neurology, University of Sherbrooke (Canada), 1998 - 2003
- M.D., University of Sherbrooke (Canada), 1998
Selected Grants and Awards
- Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
- Phase 3 randomized, open-label study to evaluate Eflornithine with Lomustine compared to Lomustine (STELLAR) alone in patients with Anaplastic Astrocytoma
- Phase 1 Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma
- Establishing a Rationale for PVSRIPO Immunotherapy in Newly Diagnosed GBM
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma
- Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112
- Phase 2 study of SYM004 for adult patients with recurrent glioblastoma
- Development of a Therapeutic for Brain Tumor Immunotherapy
- Combining PVSRIPO Immunotherapy with Lomustine for the Treatment of Recurrent GBM
- A Phase 1 Study of PTC in Patients with Advanced Solid Tumors
- Phase I/II Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Niave patients with Recurrent WHO grade IV Malignant Glioma. Study#2